ATG16L1 and neoplasm: Although tumor burden in the Atg16l1 KO group remained significantly decreased compared to the WT group (approximately a 2-fold difference in BLI signal after 4 weeks), all NSG mice administered with Atg16l1 KO CRC organoids presented with large tumor nodules (Fig. 2j).